[1] CHANG Y, JIA X, WEI F, et al. CP-25, a novel compound, protects against autoimmune arthritis by modulating immune mediators of inflammation and bone damage[J]. Sci Rep, 2016, 6: 26239. doi: 10.1038/srep26239
[2] WANG X, HE X, ZHANG CF, et al. Anti-arthritic effect of berberine on adjuvant-induced rheumatoid arthritis in rats[J]. Biomed Pharmacother, 2017, 89: 887. doi: 10.1016/j.biopha.2017.02.099
[3] XIE J, LI S, XIAO L, et al. Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients[J]. J Orthop Surg Res, 2019, 14(1): 421. doi: 10.1186/s13018-019-1492-3
[4] ONO Y, MIYAKOSHI N, KASUKAWA Y, et al. Micro-CT imaging analysis for the effects of ibandronate and eldecalcitol on secondary osteoporosis and arthritis in adjuvant-induced arthritis rats[J]. Biomed Res, 2019, 40(5): 197. doi: 10.2220/biomedres.40.197
[5] LORENZO J, HOROWITZ M, CHOI Y. Osteoimmunology: interactions of the bone and immune system[J]. Endocr Rev, 2008, 29(4): 403.
[6] SOKKA T, PINCUS T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis[J]. Arthritis Rheum, 2003, 48(2): 313. doi: 10.1002/art.10817
[7] MCCARTHY AD, CORTIZO AM, SEDLINSKY C. Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy[J]. World J Diabetes, 2016, 7(6): 122. doi: 10.4239/wjd.v7.i6.122
[8] HYUN B, SHIN S, LEE A, et al. Metformin Down-regulates TNF-α Secretion via Suppression of Scavenger Receptors in Macrophages[J]. Immune Netw, 2013, 13(4): 123. doi: 10.4110/in.2013.13.4.123
[9] WANG D, CHANG Y, WU Y, et al. Therapeutic effects of TACI-Ig on rat with adjuvant arthritis[J]. Clin Exp Immunol, 2011, 163(2): 225. doi: 10.1111/j.1365-2249.2010.04293.x
[10] IWAMOTO J, SATO Y, UZAWA M, et al. Seven years' experience with alendronate in postmenopausal Japanese women with osteoporosis[J]. Ther Clin Risk Manag, 2010, 6: 201.
[11] 杜欢, 许霞. 近5年来类风湿关节炎发病机制研究进展[J]. 辽宁中医药大学学报, 2015, 17(10): 77.
[12] FIRESTEIN GS, MCINNES IB. Immunopathogenesis of Rheumatoid Arthritis[J]. Immunity, 2017, 46(2): 183. doi: 10.1016/j.immuni.2017.02.006
[13] GRIZ L, FONTAN D, MESQUITA P, et al. Diagnosis and management of Paget's disease of bone[J]. Arq Bras Endocrinol Metabol, 2014, 58(6): 587. doi: 10.1590/0004-2730000002941
[14] HASEGAWA T, KIKUTA J, SUDO T, et al. Identification of a novel arthritis-associated osteoclast precursor macrophage regulated by FoxM1[J]. Nat Immunol, 2019, 20(12): 1631. doi: 10.1038/s41590-019-0526-7
[15] SALVATORE T, PAFUNDI PC, GALIERO R, et al. Metformin: a potential therapeutic tool for rheumatologists[J]. Pharmaceuticals (Basel), 2020, 13(9): 234. doi: 10.3390/ph13090234
[16] TAKAYANAGI H. New developments in osteoimmunology[J]. Nat Rev Rheumatol, 2012, 8(11): 684. doi: 10.1038/nrrheum.2012.167
[17] TANAKA S, TANAKA Y, ISHIGURO N, et al. RANKL: A therapeutic target for bone destruction in rheumatoid arthritis[J]. Mod Rheumatol, 2018, 28(1): 9.
[18] ZHAO J, LI Y, ZHANG H, et al. Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats[J]. J Bone Miner Metab, 2019, 37(5): 805.